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Identification and Treatment 
of Sepsis in the Field
Jamie K. Roney, DNP, RN-BC, CCRN-K
Purposes of Presentation
• Discuss historical versus new state 
of knowledge
• Identify innovative approaches to 
improving sepsis outcomes
Cases More than Doubled Between 2000 & 2008
(CDC, 2017)
Epidemiology
Compilation of Septic Shock 
Mortality
Incidence (cases per 100,000 
population)
(Trzeciak, Dellinger, & Parrillo, 2016)
Hemodynamic Profile in Septic Shock
(Trzeciak, Dellinger, & Parrillo, 2016)
In the United States…
• More than 1.5 million people develop sepsis
• At least 250,000 Americans die as a result
• Sepsis develops outside the hospital
• Accounts for 1 in 3 hospital deaths
• “Detecting sepsis early and starting immediate 
treatment is often the difference between life and 
death” CDC Director Brenda Fitzgerald, M.D.
(CDC, 2017)
Early Goal Directed Therapy 
(EGDT)
History of EGDT
• Prior to 2001, no standard for early management of 
severe sepsis and septic shock 
• The prevailing mortality was over 40-50% 
• Early goal-directed therapy (EGDT) was compared to 
standard care in a landmark clinical trial
Rivers, E. Nguyen, B., Havstad, M.A., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., Tomlanovich, M.. for the early goal 
directed therapy group. (2001).  New England Journal of Medicine, 345,(19)1368-1377.
SIRS Criteria & SBP < 
90 mmHg or Lactate>
4mmol/liter
Randomized
n=263
Standard therapy in 
ED (n=133)
Early goal directed 
therapy (n=130)
In-hospital mortality 
46.5%
In-hospital mortality 
30.5%Significance p=0.009
Rivers, E. Nguyen, B., Havstad, M.A., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., Tomlanovich, M.. for the early goal 
directed therapy group. (2001).  New England Journal of Medicine, 345,(19)1368-1377.
EGDT Validation & Adoption
• Similar outcomes reported in over 70 observational 
and randomized controlled studies comprising over 
70,000 patients 
• EGDT was largely incorporated into the first 6 hours 
of sepsis management (resuscitation bundle)
De Backer, D., & Dorman, T. (2017). Surviving Sepsis Guidelines: A continuous move toward better care of patients with 
sepsis. Jama, 317(8), 807-808. doi:10.1001/jama.2017.0059
“Early interventions in severe sepsis and septic 
shock: A review of the evidence one decade later”
Meta-analysis of over 50 publications 
looked at only the past decade of 
evidence 
– Relative risk reduction (RRR) of 0.37
– Absolute risk reduction (ARR) of 18.3%
– Number needed to treat (NNT) of 5.45
– Crude mortality reduction of 17.7%
Rivers, E.P., Katranji, M., Jaehne, K.A., Brown, S., Abou Dagher, G., Cannon, C. & Coba, V. (2012). Early interventions 
in severe sepsis and septic shock: A review of the evidence one decade later. Minerva Anestesiologica,78(6), 712-24.
Summary of implementation study Rivers et al.
Before or 
Control After Control EGDT
Number of patients
9527 9884 133 130
APACHE II score
24.2 24.2 20.4 21.4
Sex, % Males
58.15 57.3 50.4 50.8
Age (years)
63.8 62.9 64.4 67.1
Mortality before (SD)**
46.8 (26)% 29.1 (12)% 46.5% 30.5%
Relative risk reduction 0.37
0.34
Absolute risk reduction 18.3%
16.0%
NNT 5.45
6.25
Comparison of Sepsis Intervention Studies Using the Resuscitation Bundle Compared 
to the Original EGDT Study
Note. Includes before and after concurrent implementation studies. **The average mortality of each study. NNT=number needed to treat. 
Adapted from “Early Interventions in Severe Sepsis and Septic Shock: A Review of the Evidence One Decade Later”, by E.P. Rivers, M. 
Katranji, K.A. Jaehne, S. Brown, G. Abou Dagher, C. Cannon, and V. Coba, 2012, Mirnerva Anestesiologica 78(6), 712-24. Copyright 2012 by 
Edizioni Minerva Medica.

Early Goal-Directed Therapy (EGDT) in the Treatment of Severe Sepsis, Septic Shock, 
or Blood Lactate Concentration > 4 mmol/L (Grade 1C)
Crystalloid  30 ml/kg (Grade 1B); Albumin added after 
substantial crystalloids (Grade 2C)CVP line
< 8mmHg
< 65 or <90 mmHg
MAP
Vasopressors (Grade 1C): Norepinephrine first choice 
(Grade 2B); Epinephrine second-line agent (Grade 2B)
8-12 
mmHg
ScvO2
Transfuse red cells in the absence of  myocardial 
ischemia, severe hypoxemia, acute hemorrhage, 
or ischemic heart disease, for Hb < 7.0 g/dL
until Hb concentration of 7.0-9.0 g/dL (Grade 1B)
YES
Goals 
Achieved
ScvO2 
>70%
< 70%
Inotropic therapy of trial of dobutamine infusion 
up to 20 mcg/kg/min in presence of myocardial 
dysfunction or ongoing signs of hypoperfusion
despite  adequate CVP & MAP (Grade 1C)
NO
>65 & 
>90mmHg
>70%
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., … De Backer, D. P. (2017). Surviving Sepsis Campaign: International 
Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine, 45(3), 486–552. 
https://doi.org/10.1097/CCM.0000000000002255
New Evidence Arises from 
2013 & 2014 Clinical Trials
EGDT Challenges Arise
• A trio of trials (ProCESS, ARISE, and ProMISe question need for 
elements of EGDT or the need for protocolized care 
• Comparing trial conduction methodology and sepsis mortality 
trends are essential for an appropriate interpretation of these 
trials’ conclusions
• Challenges are reflected in the CMS Sepsis Core Measure 
provider assessment options
Nguyen, H. B., Jaehne, A. K., Jayaprakash, N., Semler, M. W., Hegab, S., Yataco, A. C., … Falk, J. L. (2016). Early goal-directed therapy in severe sepsis and septic shock: 
insights and comparisons to ProCESS, ProMISe, and ARISE. Critical Care, 20, 1–16. https://doi.org/10.1186/s13054-016-1288-3 
Conclusion of EGDT vs Alternative Strategies
• EGDT has been shown to have internal & external validity 
in reducing mortality 
• The trio of trials suggest alternative strategies can 
provide an equal reduction in mortality
• Due to multiple methodological differences when 
compared to the original EGDT trial (including undefined 
usual care), there is no external validity of these 
alternative strategies 
Nguyen, H. B., Jaehne, A. K., Jayaprakash, N., Semler, M. W., Hegab, S., Yataco, A. C., … Falk, J. L. (2016). Early goal-directed therapy in severe sepsis and septic shock: 
insights and comparisons to ProCESS, ProMISe, and ARISE. Critical Care, 20, 1–16. https://doi.org/10.1186/s13054-016-1288-3 
Kumar et al. CCM. 2006:34:1589-96.
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Cumulative Initiation of Effective Antimicrobial 
Therapy and Survival in Septic Shock
Funk and Kumar
Critical Care Clinics 2011 (in press)
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, … Feinstein. (2006). Duration of 
hypotension before initiation of effective antimicrobial therapy is the critical determinant of 
survival in human septic shock. Critical Care Medicine, 34(6), 1589–1596. Retrieved from 
https://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=106328256&authtype=sso&
custid=ns247570&site=ehost-live&scope=site 
Running average survival in septic shock 
based on antibiotic delay (n=2154)
For each hour’s delay in 
ad inistering antibiotics in septic 
shock, mortality increases by 7.6%
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, … Feinstein. (2006). Duration of hypotension before 
initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical 
Care Medicine, 34(6), 1589–1596. 
Sepsis Antibiotic Recommendations
• Give all antimicrobials 
simultaneously
• Broad spectrum 
coverage targeted for 
suspected type of 
infection
• Keep available on units 
to avoid pharmacy 
delays
Start in 
1 hour
(Rhodes et al., 2017)
 Norepinephrine is the recommended first-line agent (Grade 
2B)
 Epinephrine (added to or substituted for norepinephrine)
 Administer through a central catheter (Grade 1C)
 Arterial line placed for monitoring (ug)
 Vasopressin or Dopamine may be considered as second-line 
agents 
 Vasopressin 0.03 units/min can be added to norepinephrine, but not 
recommended as sole vasopressor or at higher doses (ug)
 Dopamine alternative only in highly selected patients (eg. Patients 
with low risk of tachyarrhythmias & and absolute relative 
bradycardia (Grade 2C)
 Phenylephrine not recommended (Grade 1C)
Choice of Vasopressors to Correct 
Hypotension in Septic Shock
(Rhodes et al., 2017)
CMS Sepsis Core Measure
SSC Sepsis Initial Treatment Bundle
Must be 
Completed 
in the First 3 
Hours for 
Severe 
Sepsis or 
Septic 
Shock!
1. Serum Lactate Measured 
2. Blood Cultures Prior to Antibiotic 
Administration 
3. Broad-Spectrum Antibiotics Goal of 
One Hour
4. Treat Hypotension and/or Elevated 
Lactate (>2mmol/L) with Crystalloid 
Fluids of 30 ml/kg
(Rhodes et al., 2017)
SSC Sepsis Bundle Elements
Must be Completed in the First 6 Hours for Severe 
Sepsis or Septic Shock:
1. Apply Vasopressors for Ongoing Hypotension that 
does not respond to initial fluid resuscitation) to 
maintain a mean arterial pressure (MAP)  > 65 
mmHg
2. In the event of persistent arterial hypotension 
despite volume resuscitation (septic shock) or 
initial lactate > 4 mmol/L (36 mg/dL):
• Maintain central venous pressure (CVP) > 8 mmHg
• Maintain central venous oxygen saturation (ScVO2) 
> 70%
3. Remeasure lactate if initial lactate was elevated 
(>2mmol/L) 
(Rhodes et al., 2017)
SSC Sepsis Management Considerations
1. Administer Low-Dose Steroids by a 
Standard Policy 
2. Maintain Adequate Glycemic
Control 
3. Prevent Excessive Inspiratory
Plateau Pressures
(Rhodes et al., 2017)
CMS Sepsis Core Measure Inclusions & Exclusions
• Includes
– Inpatients age 18 and over with an ICD-10-CM principal or other 
diagnosis code of Sepsis, Severe Sepsis, or Septic Shock
• Excludes
– Patients under the age of 18 years
– Patients with a LOS of greater than 120 days
– Patients with a directive for comfort measures documented by 
the provider within 3 hours of presentation of severe sepsis
– Patients with a directive for comfort measures documented by 
the provider within 6 hours of presentation
– Patients receiving intravenous antibiotics for more than 24 
hours prior to presentation with severe sepsis
CMS Sepsis Core Measure Inclusions & Exclusions
• Excludes
– Patient is a transfer from another hospital or ambulatory 
surgery center
– Patients or surrogate refuses care
• i.e. blood draw, fluid administration, or antibiotics
• Must be documented by provider or have a witnessed consent 
form stating the refusal of care present in the medical record
• Consent form can be witnessed by nurse or provider
Challenges & Opportunities
Surviving Sepsis Campaign Definition 
of Time Zero
• Will always be when the chart annotation suggests 
signs & symptoms are all present
• May be from nursing charting, laboratory flow 
sheets, physician documentation, anything with a 
time stamp
• Will equal triage time if all signs and symptoms are 
present at triage
(Rhodes et al., 2017)
ACCP/SCCM Redefining Sepsis
Sepsis versus Septic Shock
Seymour, C. W., Liu, V. X., Iwashyna, T. J., Brunkhorst, F. M., Rea, T. D., Scherag, A., … Angus, D. C. (2016). 
Assessment of clinical criteria for sepsis: For the Third International Consensus definitions for sepsis and septic 
shock (Sepsis-3). JAMA: Journal of the American Medical Association, 315(8), 762–774. 
New definition of sepsis
Sepsis is life-threatening organ 
dysfunction caused by a dysregulated 
host response to infection
(Seymour et al., 2016)
New definition of septic shock
Septic shock is a subset of sepsis in which 
profound circulatory, cellular and metabolic 
abnormalities are associated with a greater 
risk of mortality than sepsis alone
(Seymour et al., 2016)
New Sepsis Definitions
• Advantages
– Incorporates most up-to-date thinking on sepsis 
pathobiology
– Provides closest approximation possible to describing 
“what sepsis is”
• Concerns
– Of limited practical utility as they contain elements that 
cannot be clinically identified
– “organ dysfunction”
– “dysregulated host response”
Issues with the 1991 & 2001 Definitions
• SIRS based
• “Severe Sepsis” is problematic
– Different assessment criteria yield different results
• SIRS sensitivity
– SIRS is an appropriate response to infection or any other 
stimulus that activates inflammation
• Sepsis versus Severe Sepsis is confusing
– Most people say “sepsis” when they mean “severe sepsis”
– What the initial two task forces called “sepsis” is what 
most people call “infection”
Diagnosing Sepsis
SIRS versus SOFA
Systemic Inflammatory Response Syndrome (SIRS)
 Temperature > 38oC (100.4oF) or < 36oC 
(96.8oF)
 Heart Rate > 90 beats/min
 Respiratory Rate > 20 breaths/min or PaCO2 <
32 mmHg or use of a ventilator
 WBC > 12,000 or < 4,000/m3 or > 10% 
immature neutrophils (bands)
If at least TWO of the above are present, & 
Current or Recent Infection…You have SEPSIS
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, … Sibbald WJ. (2009). Definitions for sepsis and organ failure and 
guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of 
Chest Physicians/Society of Critical Care Medicine. 1992. CHEST, 136(5), e28.
ACCP/SCCM Consensus Sepsis Definitions
Sepsis = SIRS + Infection
Severe Sepsis = SIRS + Infection + End Organ 
Damage (Lactate > 2)
Septic Shock = SIRS + Infection + End Organ 
Damage (Lactate > 4)  + Refractory 
Hypotension (<90mm/hg or <40%  below 
baseline)
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, … Sibbald WJ. (2009). 
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in 
sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest 
Physicians/Society of Critical Care Medicine. 1992. CHEST, 136(5), e28.
New Recommendations Aim to Redefine Definition & 
Enhance Diagnosis of Sepsis, Septic Shock
• New method to assess for organ dysfunction is Sequential 
(Sepsis-Related) Organ Failure Assessment (SOFA)
• The new diagnostic tool is named quickSOFA or qSOFA
• If a patient has two or three components of qSOFA, 
the patient should be examined for organ failure.
• The qSOFA assessment:
– An alteration in mental status
– A decrease in systolic blood pressure of less than 100 mm Hg
– A respiration rate greater than 22 breaths/min
(Seymour et al., 2016)
SIRS versus qSOFA Screening by 
Clinicians
New Recommendations Aim to Redefine Definition & 
Enhance Diagnosis of Sepsis, Septic Shock
• The task force recommends that its report be 
designated “Sepsis-3” recognizing the two earlier 
iterations to define sepsis 
• 1991 “Sepsis-1”
• 2001 “Sepsis-2” 
(Seymour et al., 2016)
“Neutropenic sepsis: Prevention 
and management in people with 
cancer” NICE Clinical Guidelines
Bate, J., Gibson, F., Johnson, E., Selwood, K., Skinner, R., & Chisholm, J. (2013). Neutropenic sepsis: Prevention 
and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Archives of Disease in 
Childhood -- Education & Practice Edition, 98(2), 73–75. https://doi.org/10.1136/archdischild-2013-303634
Defines Neutropenia & Fever
Diagnose neutropenic sepsis in patients having 
anticancer treatment whose neutrophil count is 0.5 x 
109 per liter or lower and who have either: 
- a temperature higher than 38oC 
or 
- other signs or symptoms consistent with 
clinically significant sepsis 
(Bate et al., 2013)
Educate Caregivers & Peers
• The usual signs of infection are fever, pus, pain, swelling, and 
redness may not show up as the ANC gets lower
• These signs are caused by neutrophils fighting off germs 
• Monocytes can still cause fever in the person who has 
neutropenia
• In severe neutropenia, a fever may be the only sign of an 
infection
Diagnostic Recommendations
Endothelium
Neutrophil
Monocyte
IL-6
IL-1
TNF-
IL-6
Inflammatory Response
to Infection
Thrombotic Response
to Infection
Fibrinolytic Response
to Infection
TAFI
PAI-1
Suppressed
fibrinolysis
Factor VIIIa
Tissue Factor
COAGULATION 
CASCADE
Factor Va
THROMBIN
Fibrin
Fibrin clot
Tissue Factor
Pathobiology of Sepsis
Reprinted with permission from the National Initiative in Sepsis Education (NISE).
Microcirculatory Failure in Sepsis
(Trzeciak, Dellinger, & Parrillo, 2016)
Innovations to Improve Outcomes
• Recognition
– Lactic acid
– Physiologic change detection
– Biomarkers
– Data analytics
• Treatment
– Communication
– Escalation
– Challenge scopes of practice
• Monitoring
– Special units
• Challenge barriers
– Attitudes
– Assumptions
– Knowledge
• Caregiver Competency
– Simulation 
– Gaming
Conclusion
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